These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12515095)

  • 1. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of levofloxacin in the treatment of respiratory tract infection.
    Shah PM
    J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 7. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 8. [Moxifloxacin: results of clinical use].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
    Blasi F
    J Chemother; 2004 Apr; 16 Suppl 2():11-4. PubMed ID: 15255556
    [No Abstract]   [Full Text] [Related]  

  • 10. [Equally whether the child's lung or chronically inflamed bronchi. Acute bacterial infections have to be terminated fast].
    MMW Fortschr Med; 2004 Mar; 146(11):56. PubMed ID: 15152775
    [No Abstract]   [Full Text] [Related]  

  • 11. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 12. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 13. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 15. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 17. New insights in the treatment by levofloxacin.
    File TM
    Chemotherapy; 2004; 50 Suppl 1():22-8. PubMed ID: 15319551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of levofloxacin in low respiratory tract infection].
    Zubkov MN
    Antibiot Khimioter; 2004; 49(5):31-7. PubMed ID: 15573900
    [No Abstract]   [Full Text] [Related]  

  • 19. [Systemic antibiotherapy for the treatment of lower respiratory tract infections. Community acquired pneumonia, acute exacerbation of obstructive chronic bronchitis].
    Chidiac C; ;
    Med Mal Infect; 2011 May; 41(5):221-8. PubMed ID: 21106313
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.